Generics The US Federal Trade Commission today announced a proposed consent order settling charges that Watson Pharmaceutical' of Robin Hood Holdings, owner of Arrow Pharmaceuticals, would have harmed consumers by eliminating future competition for important generic drugs used to treat Parkinson's disease notably (cabergoline) and the side effects of chemotherapy (dronabinol). The Commission's order requires the firms to sell assets related to the two drugs to FTC-approved buyers and to ensure the acquirers have the means to compete effectively in the future. 4 December 2009